Blog ISPOR replacement

Improving healthcare in a sustainable fashion is the shared goal of delegates at the ISPOR 17th Annual European Congress, currently underway in Amsterdam. We know our healthcare systems face many challenges as we strive for the triple aim of better outcomes, higher quality care and reduced total cost. Each stakeholder has a different role to play in overcoming these challenges but one thing is clear from the sessions at the conference - collaboration will be essential to success. 

Cost effectiveness has been an important factor in decision making for a number of HTA authorities in Europe including NICE. However, there are wider issues at play in terms of enabling access to innovative medicines for patients. 

In the plenary session, Carin A. Uyl-de Groot, PhD, observed that factors affecting outcomes in the real world include delivery systems, clinical guidelines, patient characteristics and local priorities. This suggests that properly integrated, patient centric care requires cooperation from manufacturers, payers, prescribers and health care authorities. Evidence can be a key driver of trust between these groups and the one thing they all have in common is an increasing desire for evidence of value. This is what the ISPOR conference is really about: evidence not only of cost effectiveness but real world outcomes and budget impact. 

There is a diverse group in attendance, representing not only the pharmaceutical and medical device industry and its advisors, but also those who work in or advise regulatory authorities, HTA or pricing and reimbursement agencies, as well as practicing physicians and others. We are here discussing just how to generate the right evidence to meet the triple aim. 

Quintiles' John Doyle and Eric Faulkner presented as part of a panel on how to generate the right evidence to treatments for rare diseases. They discussed the need to consider equity and budget impact when looking at orphan drugs given their price and the number of patients impacted. In a separate issue panel, Anke van Engen, Senior Director, Consulting at Quintiles, moderated a panel discussing “Optimizing HTA - Should we Adjust Overall Survival Estimates for Treatment Switching in Oncology?” The panel discussed issues in analyzing data to meet HTA authorities needs as they assess oncology products. She highlights variations in approaches by different national authorities and how robust statistical methods can be used to make corrections to data quality where patients switch between control and experimental treatment arms in oncology trials. 

Multiple research posters were presented based on Quintiles’ HTA Accelerator, an online platform used to gather data and generate strategic insights to form a complete picture of stakeholder requirements in specific markets. Topics covered included analysis of HTA and policy decisions made in Germany, the UK, Latin America, Italy, and Spain.

Topics in this blog post: Biopharma, Evidence, EMA, EU, Healthcare Cost, Patient Outcomes, Value